Welcome, Guest. Please login or register.
May 30, 2024, 02:39:02 pm

Login with username, password and session length


Members
Stats
  • Total Posts: 773610
  • Total Topics: 66392
  • Online Today: 272
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 0
Guests: 241
Total: 241

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: EBT-101  (Read 12120 times)

0 Members and 1 Guest are viewing this topic.

Offline MitchMiller

  • Member
  • Posts: 672
EBT-101
« on: September 17, 2021, 09:42:55 pm »
After reading about it for a few years, CRISPR is about to be trialed in humans to excise HIV from cells.  The hope is that enough virus (including latent virus) can be removed from the body to accomplish a functional cure.  It has already worked on primates that have SIV. 

https://www.phillymag.com/healthcare-news/2021/03/05/excision-biotherapeutics-temple-hiv-clinical-trial/

Offline em

  • Member
  • Posts: 691

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 22,508
  • Threads: @jim16309
    • Social Media: Threads
Re: EBT-101
« Reply #2 on: November 05, 2021, 12:04:32 pm »
Quote
human trials ,    any thoughts

The same thoughts I had in 2016 about Dr. Khalili work with CRISPR when they cured a mouse and in 2020 on the primate. Scientifically interesting but no other thoughts at such an early stage.


HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

My Instagram
Threads

Offline CircularNatural

  • Member
  • Posts: 45
  • 🇦🇷 Joined Sept 2021
Re: EBT-101
« Reply #3 on: November 05, 2021, 04:09:10 pm »
It's so interesting to follow this kind of novel treatments... one can only be hopeful  ;D :D :)
🇦🇷 "Hope is the only thing stronger than fear."

Offline Da2020

  • Member
  • Posts: 41
Re: EBT-101
« Reply #4 on: January 23, 2022, 05:30:43 pm »
They have posted it on clinicaltrails.gov in December and recently updated the trail start date as Jan 2022. If only they would start the trail. It is a very interesting approach and trail. They want to start ATI within 3 months which is definitely very interesting

Offline em

  • Member
  • Posts: 691
Re: EBT-101
« Reply #5 on: January 24, 2022, 07:14:59 am »

Offline Da2020

  • Member
  • Posts: 41
Re: EBT-101
« Reply #6 on: February 20, 2022, 08:19:03 pm »
They have started the trail in St.Louis, MO

Offline Da2020

  • Member
  • Posts: 41
Re: EBT-101
« Reply #7 on: May 22, 2022, 04:39:53 pm »
They have presented a poster demonstrating, no off target cuts . At least we know its not going to create zombies :)

Offline geobee

  • Member
  • Posts: 376
Re: EBT-101
« Reply #8 on: May 31, 2022, 12:46:10 am »
Another breathless "milestone" -- demonstrated "efficacy" against HIV.

https://www.americangene.com/news-releases/agt-hiv-blood-markers-of-efficacy-more-patients/

Offline Da2020

  • Member
  • Posts: 41
Re: EBT-101
« Reply #9 on: May 31, 2022, 02:49:06 pm »
Another breathless "milestone" -- demonstrated "efficacy" against HIV.

https://www.americangene.com/news-releases/agt-hiv-blood-markers-of-efficacy-more-patients/

They have reaped this news in February, there actually is a separate thread tracking them

Offline Cosmicdancer

  • Member
  • Posts: 199
Re: EBT-101
« Reply #10 on: September 18, 2022, 11:03:09 am »
Excision BioTherapeutics Doses First Participant in EBT-101 Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV

* EBT-101 is an in vivo CRISPR-based therapeutic designed to remove HIV proviral DNA from affected cell reservoirs

* First-in-human study will evaluate the safety and efficacy of EBT-101 in participants who chronically suppress HIV with daily antiretroviral therapy

* EBT-101 has been well tolerated to-date and the trial is proceeding as planned

SAN FRANCISCO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced that the first participant has been dosed in the Phase 1/2 clinical trial of EBT-101 for human immunodeficiency virus type 1 (HIV-1). The participant was dosed in July 2022, with initial findings indicating EBT-101 has been well tolerated to-date. The participant continues to be monitored for safety and is expected to qualify for analytical treatment interruption (ATI) of their background anti-retroviral therapy (ART) in an evaluation of a potential cure.

“Dosing the first participant with EBT-101 is a landmark event that solidifies Excision’s position as a pioneer in gene editing,” said Daniel Dornbusch, Chief Executive Officer of Excision. “It is the first time a CRISPR-based therapy targeting an infectious disease has been administered to a patient and is expected to enable the first ever clinical assessment of a multiplexed, in vivo gene editing approach. We were able to reach this watershed moment thanks to years of innovative work by leading scientists and physicians, to whom we are immensely grateful. With this achievement, Excision has taken a major step forward in developing a one-time treatment that could transform the HIV pandemic by freeing affected people from life-long disease management and the stigma of disease."

https://www.tmcnet.com//usubmit/2022/09/15/9674271.htm
Summer, 2007 - &$#@?
November, 2007 - Tested poz, 300,000 vl, 560 cd4
Feb, 2008 - 57,000 vl, 520 cd4, started Atripla
2/2008 - 5/2015 - undetectable on Atripla
May, 2015 - UD, switched to Complera
September, 2015 - UD, 980 cd4, switched to Stribild (Complera interacted with acid reflux medication)
January, 2016 - Stribild, UD, 950 cd4
June, 2016 - UD, 929 cd4

Offline Cosmicdancer

  • Member
  • Posts: 199
Re: EBT-101
« Reply #11 on: August 06, 2023, 09:53:32 am »
The article is brief, so here it is in its entirety. Given that the first person treated with this CRISPR-Cas9 therapy was reported in September of last year, I assume that it has been found to be safe, although perhaps it's too early to know about its efficacy.


The Food and Drug Administration (FDA) has granted Fast Track designation to EBT-101, an investigational gene therapy, for the treatment of HIV-1.

EBT-101 uses an adeno-associated virus to deliver CRISPR-Cas9 and dual guide RNAs, which target and excise large portions of the HIV genome. The treatment is delivered as a single intravenous infusion and is being sought as the first curative therapy for HIV-1.

A phase 1/2 trial (ClinicaTrials.gov Identifier: NCT05144386) is evaluating the gene therapy in adult patients with HIV-1 (18 to 65 years old) who are on stable antiretroviral therapy (ART) with HIV RNA below the level of detection. The primary endpoint of the study is to assess safety and tolerability; efficacy assessments will also be conducted. At week 12, patients will be assessed for eligibility for an analytical treatment interruption of their background ART.

After 48 weeks post infusion, patients will be eligible to continue in a long-term follow-up study (ClinicalTrials.gov Identifier: NCT05143307) that is expected to last 15 years.

“We are pleased with the FDA’s decision to grant Fast Track designation to EBT-101,” said Daniel Dornbusch, Chief Executive Officer of Excision. “This designation underscores the importance of finding a cure for people living with HIV and bolsters Excision’s efforts to rapidly develop potentially curative therapies for significant unmet medical needs.”

The FDA’s Fast Track designation helps to accelerate the development and review of products for serious and life-threatening conditions where no treatment exists or where the investigational therapy is likely to provide an advantage over currently available treatments.

https://www.empr.com/home/news/drugs-in-the-pipeline/crispr-based-gene-therapy-candidate-fast-tracked-for-hiv-treatment/
Summer, 2007 - &$#@?
November, 2007 - Tested poz, 300,000 vl, 560 cd4
Feb, 2008 - 57,000 vl, 520 cd4, started Atripla
2/2008 - 5/2015 - undetectable on Atripla
May, 2015 - UD, switched to Complera
September, 2015 - UD, 980 cd4, switched to Stribild (Complera interacted with acid reflux medication)
January, 2016 - Stribild, UD, 950 cd4
June, 2016 - UD, 929 cd4

Offline Towel

  • Standard
  • Member
  • Posts: 15
  • Hello!
Re: EBT-101
« Reply #12 on: August 06, 2023, 03:49:25 pm »
That seems hopeful. But even if they did discover a cure, it would beat least another 5 years and further safety testing before it starts to reach the general population, no?

Offline Cosmicdancer

  • Member
  • Posts: 199
Re: EBT-101
« Reply #13 on: August 08, 2023, 08:56:00 am »
I have no idea about the timeline, but I'm sure it would be years before this therapy is approved by the FDA. But given that this clinical trial started 11 months ago, it looks like they may have reached the 48 week post infusion end point for trial participants.  Perhaps some of the participants that began treatment interruption 13 weeks after the infusion are undetectable or have low viral loads. I'm just speculating about why the FDA is fast tracking this. If there's something newsworthy, I'm sure it will be reported at the next International conference on retroviruses (CROI) in the Spring of 2024. Meanwhile, I'm glad we have effective treatments with HAART.
Summer, 2007 - &$#@?
November, 2007 - Tested poz, 300,000 vl, 560 cd4
Feb, 2008 - 57,000 vl, 520 cd4, started Atripla
2/2008 - 5/2015 - undetectable on Atripla
May, 2015 - UD, switched to Complera
September, 2015 - UD, 980 cd4, switched to Stribild (Complera interacted with acid reflux medication)
January, 2016 - Stribild, UD, 950 cd4
June, 2016 - UD, 929 cd4

Offline xxxyyy

  • Standard
  • Member
  • Posts: 4
Re: EBT-101
« Reply #14 on: August 21, 2023, 02:28:48 pm »
.
« Last Edit: August 21, 2023, 02:38:13 pm by Jim Allen »

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 22,508
  • Threads: @jim16309
    • Social Media: Threads
Re: EBT-101
« Reply #15 on: August 21, 2023, 02:39:55 pm »
« Last Edit: August 21, 2023, 02:43:26 pm by Jim Allen »
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

My Instagram
Threads

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 22,508
  • Threads: @jim16309
    • Social Media: Threads
Re: EBT-101
« Reply #16 on: August 21, 2023, 02:42:16 pm »
General reminder for those living with HIV regarding posting in this Forum section: https://forums.poz.com/index.php?topic=11292.0
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

My Instagram
Threads

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 22,508
  • Threads: @jim16309
    • Social Media: Threads
Re: EBT-101
« Reply #17 on: August 31, 2023, 11:40:08 am »
POZ.com article in full: https://www.poz.com/article/crispr-gene-editing-removes-virus-cells

In Brief:
Quote
A single injection of a novel CRISPR gene-editing therapy known as EBT-100 safely and effectively removed simian immunodeficiency virus (SIV)—a virus related to HIV—from viral reservoirs in monkeys, according to a report in Nature Gene Therapy. The first human trial of the EBT-100 started last year.

“The long timeframe of the study and the use of high doses of the gene-editing construct help confirm the safety of EBT-001,” lead study author Tricia Burdo, PhD, of the Lewis Katz School of Medicine at Temple University, said in a news release. “Our preclinical work in non-human primates was essential for allowing us to establish the criteria for applying EBT-101 in clinical studies and enabling the [Food and Drug Administration] authorization for an HIV-specific gene-editing therapy to move forward.”

Senior investigator Kamel Khalili, PhD, of Temple University, and colleagues have been studying gene therapy to cure HIV for more than a decade. In 2014, they published a groundbreaking study showing that a CRISPR-Cas9 tool could delete a segment of integrated proviral DNA that includes the gene for HIV’s Gag protein, which is necessary for viral replication. A study published in 2019 showed that the technique could cut out integrated HIV genes and clear latent viral reservoirs in humanized mice. The next year, an early study in monkeys showed that the CRISPR tool excised segments of integrated SIV from blood cells and viral reservoir tissues.

“Our study supports safety and demonstrates evidence of in vivo SIV editing of a CRISPR gene-editing technology aimed at the permanent inactivation of virus in a broad range of tissues in a large, preclinical animal model, using a one-time injection of the treatment,” Khalili said. “The outcome of the preclinical model set the stage for the ongoing clinical trial of EBT-101.”
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

My Instagram
Threads

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 22,508
  • Threads: @jim16309
    • Social Media: Threads
Re: EBT-101
« Reply #18 on: November 04, 2023, 04:53:17 am »
https://www.poz.com/article/crispr-hiv-gene-therapy-looks-safebut-work

Quote
EBT-101, a novel CRISPR-based gene-editing therapy from Excision BioTherapeutics, was not associated with any serious adverse events in the first three treated study participants, researchers reported last week at the European Society for Gene & Cell Therapy annual meeting in Brussels. But the presentation was frustratingly short on data about whether the treatment works to control HIV.

According to the company, study participants will be followed for 48 weeks after EBT-101 administration, and all eligible participants will be assessed for sustained viral suppression after stopping antiretrovirals in an analytical treatment interruption starting at week 12. After the initial study, they will be enrolled in a long-term follow-up study (EBT-101-002).


The first participant who received EBT-101 in the summer of 2022 is already well past the 12-week mark when the treatment interruption should have commenced, but Excision has not provided any further information about his status. The company said in its press release that additional data would be presented in 2024.

While these initial results appear promising, it is far too soon to say that a functional cure for HIV is on the horizon.

“Scientists tell me that this is going to be part of a cure some day. And I shrug my shoulders and say, ‘Here we go again,’” long-term survivor and advocate Matt Sharp told the San Jose Mercury News. “Now we just have to get the research done. We’ve got to have hope, because the epidemic isn’t over.”



So, basically, there is no substantial update. I see that some other popular media outlets have been publishing misleading headlines this past week; I suppose it is the same old story: Publish whatever sells papers, gets clicks, improves your stock position or gets you funding, and the truth and damage caused be dammed.

 
« Last Edit: November 04, 2023, 04:59:17 am by Jim Allen »
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

My Instagram
Threads

Offline gorka

  • Member
  • Posts: 103
Re: EBT-101
« Reply #19 on: November 05, 2023, 06:14:35 pm »
not sure about this group but number of groups are gearing up for cell therapy or gene therapy approach using crispr.  it has been very succesful for some cancers so far. hoping it will eventually work for hiv

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 22,508
  • Threads: @jim16309
    • Social Media: Threads
Re: EBT-101
« Reply #20 on: May 13, 2024, 11:56:49 am »
I have not seen all the details yet, but if correct it's a flop in terms of an HIV cure, even the one patient out of five reaching 16 weeks is nothing to praise with standard modern ART. *

Excision’s CRISPR-Based HIV Treatment Fails to Show Curative Potential in Early Study

https://www.biospace.com/article/excision-s-crispr-based-hiv-treatment-fails-to-show-curative-potential-in-early-study-/

Quote
Excision BioTherapeutics’ attempt to use a CRISPR-based gene editing therapy to cure HIV has failed an early-stage study, according to several media reports on Friday.

Results from the Phase I trial of five patients showed that Excision’s CRISPR therapeutic did not strongly suppress the HIV virus. Three patients who were taken off of antiretroviral therapy soon developed viral rebound and needed to resume conventional treatments, according to reporting by STAT News.

Still, Excision’s approach did show signs of promise. One patient was able to keep the virus at bay for 16 weeks after stopping antiretroviral treatment before rebounding.

I'll keep my eyes open for more details when they become available and post them here.



* HIV Time to Viral Rebound After Interruption of Modern ART.
https://forums.poz.com/index.php?topic=76642.msg
« Last Edit: May 13, 2024, 12:01:11 pm by Jim Allen »
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

My Instagram
Threads

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 22,508
  • Threads: @jim16309
    • Social Media: Threads
Re: EBT-101
« Reply #21 on: May 14, 2024, 10:47:31 am »
I see poz.com are now also reporting this update.

CRISPR HIV Gene Therapy Disappoints in Early Study
https://www.poz.com/article/crispr-hiv-gene-therapy-disappoints-early-study

Quote
EBT-101 recipients who stopped antiretrovirals experienced HIV viral rebound, but similar therapies may hold more promise for herpes and hepatitis B
.
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

My Instagram
Threads

Offline harleymc

  • Member
  • Posts: 1,528
Re: EBT-101
« Reply #22 on: May 21, 2024, 09:06:50 pm »

 


Terms of Membership for these forums
 

© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.